WIPO Re:Search

Re:Search - Details

Trachoma vaccine

SUBMISSION ID 625

Contact Details

Provider NIH
Partnership Hub Coordinator Name BIO Ventures for Global Health
221 Main Street, Suite 1600
San Francisco, CA 94105
USA
Tel: +1 415 446 94 43
partnershiphub@bvgh.org

Submission Summary

TitleTrachoma vaccine
Executive Summary/Abstract This technology claims vaccine compositions that comprise an immunologically effective amount of PmpD protein from C. trachomatis. Also claimed in the application are methods of immunizing individuals against C. trachomatis. PmpD is an antigenically stable pan-neutralizing target that, in theory, would provide protection against all human strains, thus allowing the development of a univalent vaccine that is efficacious against both blinding trachoma and sexually transmitted disease.
Keywords Trachoma vaccine

Disease Selection

Disease Trachoma
Comment
Name(s) of Infectious Organism(s) Chlamydia trachomatis
Vector(s)
Human Target Organ(s)
Mechanism of Action (MoA)
Molecular or Cellular Target Name(s)

Type of Data

Type of Data Intellectual Property







INTELLECTUAL PROPERTY DATA SUBFIELDS

IP Description

 
Summary/Abstract Text Chlamydia Vaccine; More information is available here: http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=1610 "Chlamydia trachomatis is an obligate intracellular bacterial pathogen that colonizes and infects oculogenital mucosal surfaces. The organism exists as multiple serovariants that infect millions of people worldwide. Ocular infections cause trachoma, a chronic follicular conjunctivitis that results in scarring and blindness. The World Health Organization estimates that 300–500 million people are afflicted by trachoma, making it the most prevalent form of infectious preventable blindness. Urogenital infections are the leading cause of bacterial sexually transmitted disease in both industrialized and developing nations. Moreover, sexually transmitted diseases are risk factors for infertility, the transmission of HIV, and human papilloma virus-induced cervical neoplasia. Control of C. trachomatis infections is an important public health goal. Unexpectedly, however, aggressive infection control measures based on early detection and antibiotic treatment have resulted in an increase in infection rates, most likely by interfering with natural immunity, a concept suggested by studies performed in experimental infection models. Effective management of chlamydial disease will likely require the development of an efficacious vaccine. This technology claims vaccine compositions that comprise an immunologically effective amount of PmpD protein from C. trachomatis. Also claimed in the application are methods of immunizing individuals against C. trachomatis. PmpD is an antigenically stable pan-neutralizing target that, in theory, would provide protection against all human strains, thus allowing the development of a univalent vaccine that is efficacious against both blinding trachoma and sexually transmitted disease."
Keywords
References 103 6 :1894-1899. Epub 2006 Jan 30. [PubMed abs]; DD Crane et al. Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc. Natl Acad Sci USA. 2006 Feb 7

Benefits for Disease

 
Field(s) of IP/Know-how Application
How to use IP/Know-how for Disease
Potential Benefits for Disease Application Prevention of trachoma

Publication/Patent Status

 
Proprietary IP or Know-How Yes
How many Patent Families
How many Granted Patents
Granted Patent Reference Number(s) HHS, Reference No. E-031-2006/0; US, Application No. 12/087,952 filed 16 Jul 2008; PCT, Application No. PCT/US2007/001213 filed 16 Jan 2007
How many Pending Patents
Pending Patent Reference Number(s)
How many Abandoned Patents
Abandoned Patent Reference Number(s)

Collaboration Status

 
In house only No
Names of
Partners The NIAID, Laboratory of Intracellular Parasites, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize PmpD vaccine development
Service Providers
Academic Centers
Public Private Partnerships
Funding Agencies
Other Collaborators